Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs

Abstract

Aims In England and Wales, the National Diabetes Audit (NDA) assesses the quality of management of type 2 diabetes (T2D) in primary care using treatment targets for HbA1c ≤58 mmol/mol, total cholesterol <5 mmol/L and blood pressure ≤140/80 mm Hg. We quantified the impact of variation in achieving these targets on health outcomes and healthcare costs across general practitioners' (GP) practices. Methods Summary of characteristics of T2D patients from the 2015–2016 NDA were used to generate representative populations of T2D patients. The UKPDS Outcomes Model 2 was used to estimate long‐term health outcomes and healthcare costs. The effects of achieving treatment targets on these outcomes were evaluated using regression models. Results Achieving more of the HbA1c, cholesterol and blood pressure targets led to a lower incidence of diabetes‐related complications. Approximately 0.5 (95% CI, 0.4‐0.6) quality‐adjusted life years (QALYs) and 0.6 (95% CI, 0.4‐0.7) years of life (LYs) were gained by T2D patients over a lifetime for each additional target met. The projected healthcare cost savings arising from fewer diabetes‐related complications as the result of achieving one, two or three targets compared to none were £859 (95% CI, £553‐£1165), £940 (95% CI, £485‐£1395) and £1037 (95% CI, £414‐£1660) over a patient's lifetime. A typical GP practice in the lowest performing decile (average, 371 T2D patients per practice, with 27% achieving all targets) is projected to gain 201 (95% CI, 123‐279) QALYs and 231 (95% CI, 133‐329) LYs, if all T2D patients achieved all three targets. Conclusions Substantial gains in health outcomes and reductions in healthcare costs could be achieved with further improvements in attainment of HbA1c, cholesterol and blood pressure targets for T2D patients.

The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis

“…Despite the small effect sizes, the results highlight an interesting effect of the use of probiotic, prebiotic or synbiotic supplements on lipid profile, which was enhanced (total cholesterol and triacylglycerol levels were decreased, whereas HDL-cholesterol levels were increased). As an enhanced lipid profile is usually associated with a low incidence of diabetesrelated complications, it is tempting to speculate that these results could be reproduced [73]. However, clinical outcomes were not evaluated in the majority of the studies we retrieved, and the follow-up period was too short to determine any longterm effects on morbidity/mortality.…”

Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018

“…Our findings suggest that patients with type 2 diabetes have diverse care needs, as illustrated by the heterogeneity in their care utilization, therefore a more tailored, patient-centered approach to diabetes care could be meaningful. Such an approach can lead to better controlled glycated hemoglobin (HbA1c) levels, cholesterol and blood pressure, and may consequently contribute to long-term health improvement and prevention of type 2 diabetes-related complications [ 40 , 49 , 50 ]. As type 2 diabetes-related complications and comorbidities are found to significantly increase healthcare utilization and expenditures of type 2 diabetes patients, these health improvements could lead to a reduction in overall costs, subsequently promoting the sustainability of healthcare systems [ 6 – 9 , 26 , 51 – 54 ].…”

Association of musculoskeletal pain with the achievement of treatment targets for type 2 diabetes among primary care patients

“…Achieving treatment goals for glycosylated haemoglobin A1c (HbA1c), low-density-lipoprotein cholesterol (LDL), and systolic blood pressure (SBP) is considered an important dimension in the T2D care in order to decrease T2D-related complications and mortality [10][11][12][13][14]. Worryingly, only under half of the T2D patients record sufficient levels of these outcomes globally [15].…”